PT  - JOURNAL ARTICLE
AU  - Struja, Tristan
AU  - Matos, João
AU  - Lam, Barbara
AU  - Cao, Yiren
AU  - Liu, Xiaoli
AU  - Jia, Yugang
AU  - Sauer, Christopher M.
AU  - D’Couto, Helen
AU  - Dankwa-Mullan, Irene
AU  - Celi, Leo Anthony
AU  - Waschka, Andre Kurepa
TI  - Evaluating equitable care in the ICU: Creating a causal inference framework to assess the impact of life-sustaining interventions across racial and ethnic groups
AID  - 10.1101/2023.10.12.23296933
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.12.23296933
4099  - http://medrxiv.org/content/early/2023/10/12/2023.10.12.23296933.short
4100  - http://medrxiv.org/content/early/2023/10/12/2023.10.12.23296933.full
AB  - Background Variability in the provision of intensive care unit (ICU)-interventions may lead to disparities between socially defined racial-ethnic groups.Research Question We used causal inference to examine the use of invasive mechanical ventilation (IMV), renal replacement therapy (RRT), and vasopressor agents (VP) to identify disparities in outcomes across race-ethnicity in patients with sepsis.Study Design and Methods Single-center, academic referral hospital in Boston, Massachusetts, USA. Retrospective analysis of treatment effect with a targeted trial design categorized by treatment assignment within the first 24 hours in the MIMIC-IV dataset (2008- 2019) using targeted maximum likelihood estimation. Of 76,943 ICU stays in MIMIC-IV, 32,971 adult stays fulfilling sepsis-3 criteria were included. The primary outcome was in-hospital mortality. Secondary outcomes were hospital-free days, and occurrence of nosocomial infection stratified by predicted mortality probability ranges and self-reported race-ethnicity. Average treatment effects by treatment type and race-ethnicity, Racial-ethnic group (REG) or White group (WG), were estimated.Results Of 19,419 admissions that met inclusion criteria, median age was 68 years, 57.4% were women, 82% were White, and mortality was 18.2%. There was no difference in mortality benefit associated with the administration of IMV, RRT, or VP between the REG and the WG. There was also no difference in hospital-free days or nosocomial infections. These findings are unchanged with different eligibility periods.Interpretation There were no differences in the treatment outcomes from three life-sustaining interventions in the ICU according to race-ethnicity. While there was no discernable harm from the treatments across mortality risk, there was also no measurable benefit. These findings highlight the need for research to understand better the risk-benefit of life-sustaining interventions in the ICU.Competing Interest StatementAll authors confirm that they do not have a conflict of interest associated with this manuscript. YC and YJ are currently also affiliated with Verily life science, SSF, CA.Funding StatementThis study was supported by unrestricted educational grants to Celi (NIBIB, R01 EB001659), Struja (Swiss National Science Foundation, P400PM_194497 / 1), Matos (Fulbright / FLAD Grant, Portugal, AY 2022/2023), and Sauer (German Research Foundation funded UMEA Clinician Scientist Program, FU356/12-2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at PhysioNet.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the study are available in MIMIC-IV with the identifier doi.org/10.1093/jamia/ocx084 publicly available on PhysioNet https://physionet.org/content/mimiciv/2.2/